All Online

1 - 12 of 30 results

Refine

Active filters

Diabetes

Cardiovascular Risk in T2DM

1.50 CME/MOC
1.48 AANP | 1.13 Pharmacology


0.28 CME CREDIT

Primary care clinicians (PCCs) are ideally suited to educate and advise people with type 2 diabetes about basal insulin. This program will inform PCCs about current recommendations and advances in the safe and effective use of basal insulin, so they can provide individualized, appropriate care for their patients.


0.75 CME CREDIT

Two leading experts in type 2 diabetes management will review the benefits and limitations of GLP-1 receptor agonists, including a new oral agent in this class, by providing expert syntheses of clinical trial data and demonstrating how to turn this information into useful, actionable guidance for routine patient care.


0.75 CME CREDIT

This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.


0.75 CME CREDIT

In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).


0.75 CME CREDIT

During this session (part 2 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for GLP-1 RAs and DPP-4 inhibitors. Using 2 patient cases, they discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure, and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


0.58 CME CREDIT

During this session (part 3 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for SGLT2 inhibitors and use a patient case to discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


1 CME CREDIT

Diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. In this session, faculty will review current data on the renoprotective properties of SGLT2 inhibitors and explain the guideline recommendations for their use in patients with type 2 diabetes and kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/4/2019, and they are subject to change as new information is published.


0.52 CME CREDIT

0.52 CME CREDIT

An Interactive Webcast: Initiating and Managing Insulin

0.50 CME/MOC
0.52 AANP | 0.20 Pharmacology


0.25 CME CREDIT

During this session (part 1 of 3 webcast videos), Dr. Tina Thethi reviews the association between type 2 diabetes and cardiovascular disease as well as provides an overview of the American Diabetes Association guidelines designed to help individualize therapy for patients with T2DM and concurrent heart failure and/or atherosclerotic cardiovascular disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.